Andrew Poklepovic, MD
Internal Medicine · Richmond, VANPI 1356550800
Payments from drug & device makers
Across 222 payments — averaging $20,888 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2.5M
- Merck$1.1M
- E.r. Squibb & Sons, L.L.C.$383K
- Incyte Corporation$223K
- Iovance Biotherapeutics, Inc.$130K
- Ascendis Pharma Endocrinology Inc$112K
- plus $237K from 11 others
What the payments were for
- Consulting fees$22,60839%
- Speaking & faculty fees$33,71558%
- Travel & lodging$5681%
- Food & beverage$1,2262%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 60 | $2,463,310 |
| Merck | 39 | $1,088,905 |
| E.r. Squibb & Sons, L.L.C. | 44 | $383,030 |
| Incyte Corporation | 4 | $222,673 |
| Iovance Biotherapeutics, Inc. | 11 | $130,128 |
| Ascendis Pharma Endocrinology Inc | 12 | $111,895 |
| Regeneron | 16 | $101,997 |
| Genentech, Inc. | 15 | $88,746 |
| Exelixis Inc. | 1 | $27,012 |
| Novartis | 3 | $8,361 |
| Bristol Myers Squibb | 8 | $5,700 |
| Amgen | 2 | $4,950 |
| Springworks Therapeutics, Inc. | 3 | $228 |
| Eisai Inc. | 1 | $105 |
| Tempus AI, Inc | 1 | $22 |
| Immunocore Limited | 1 | $19 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,637,096 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BraftoviEncorafenib | 15 | $218,050 |
| MektoviBinimetinib | 15 | $213,936 |
| Ondansetron Hcl | 15 | $358 |
| Oxycodone Hcl | 18 | $337 |
| Prochlorperazine Maleate | 12 | $164 |
| Prednisone | 21 | $125 |
| Tramadol Hcl | 12 | $117 |
| Levothyroxine Sodium | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
- Sherman BakerRichmond$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.